6 Sept 2026
Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agentsPublisher siteFuture Medicinal Chemistry, Angiogenesis and VEGF in Cancer
UniversitiesIbrahim H. Eissa
Active, last published 2026
In synthesis and biological activity
Ibrahim H.
Eissa
Scholar“Research focused on Synthesis and biological activity and adjacent fields.”
Al-Azhar University
Claim Your Profile54
H-index
8.1k
Citations
Ibrahim has not officially claimed their profile. If you are Ibrahim, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
brahim H. Eissa is a researcher working on Synthesis and biological activity. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Ibrahim's work has been cited 8,131 times across 6 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Synthesis and biological activity×101Angiogenesis and VEGF in Cancer×54Computational Drug Discovery Methods×46Bioactive Compounds and Antitumor Agents×41Cancer therapeutics and mechanisms×40
04 · Where I am
Affiliations
Affiliation on published researchAl-Azhar UniversityDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
55 works26 Aug 2026
Rational design of a bis-acetanilide hydrazone–thiourea hybrid as a potent VEGFR-2 inhibitor: in silico and in vitro evaluationsPublisher siteChemical Papers, Angiogenesis and VEGF in Cancer
5 Aug 2026
New theobromine-derived EGFR inhibitor: integrated in silico studies and in vitro evaluationsPublisher siteJournal of Molecular Structure, Computational Drug Discovery Methods
28 May 2026
Development of a Novel Benzanilide Derivative Targeting VEGFR-2: Computational Modeling and <i>In Vitro</i> Anticancer ValidationPublisher siteJournal of Computational Biophysics and Chemistry, Angiogenesis and VEGF in Cancer
25 May 2026
New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activityPublisher siteBioorganic Chemistry, Microtubule and mitosis dynamics
1 May 2026
Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer ActivityPublisher siteDrug Development Research, Angiogenesis and VEGF in Cancer
2 Apr 2026Open access
Broad-spectrum antiviral potential of vitexin and isovitexin from Jatropha integerrima: in vitro cytoprotective effects and in silico insightsPublisher siteNaunyn-Schmiedeberg s Archives of Pharmacology, Natural Antidiabetic Agents Studies
1 Mar 2026
Thiadiazole‐Derived <scp>VEGFR</scp> ‐2 Inhibitors: From Design to Anticancer EvaluationPublisher siteChemical Biology & Drug Design, Angiogenesis and VEGF in Cancer
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Ibrahim?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you